COMMUNIQUÉS West-GlobeNewswire

Glass House Brands Completes Previously Announced Warrant Redemption
29/05/2026
LONG BEACH, Calif. and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF) today announced the [...]
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
29/05/2026
Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies [...]
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
29/05/2026
SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “ [...]
EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
29/05/2026
EDAP Announces Corporate Name Change to FocalTherics ™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June 1, 2026 Company [...]
Mud Wtr Reviews: Is This Mushroom Coffee Alternative Worth Drinking?
29/05/2026
Mud Wtr Reviews: Is This Mushroom Coffee Alternative Washington dc, May 29, 2026 (GLOBE NEWSWIRE) -- Mud Wtr Reviews: Is This Mushroom Coffee Alternative Worth Drinking? If you have seen Mud Wtr ads everywhere and [...]
Spectral Medical Announces PMA Submission to U.S. FDA for PMX
29/05/2026
TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the [...]
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
29/05/2026
Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Agios [...]
PICARD MEDICAL, INC. Issues Letter to Shareholders
29/05/2026
TUCSON, Ariz., May 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), parent company of SynCardia Systems LLC, maker of the world’s first and only total [...]
Seer Files ITC Complaint Against Nanomics
29/05/2026
Seeks Exclusion Order Barring Importation of Infringing Proteonano Kits and Workstations REDWOOD CITY, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased [...]
The Next Great AI Revolution May Be Drug Delivery
29/05/2026
DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet [...]
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
29/05/2026
KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision [...]
SRx Health Solutions Invests in Uber Technologies, Inc. and Provides Shareholders with Portfolio Update
29/05/2026
Reduced long position in Compass, Inc., reduced short exposure to Bitcoin and added selective hedges in select international markets EMJX stress model turned STRESS from MIXED this week – the first negative market [...]
Cannabix Expands BreathLogix Alcohol Screening Technology into Mining, Municipal and Aviation Sectors in Australia
29/05/2026
VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath devices is [...]
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
29/05/2026
Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
SkyAI Appoints Veteran Finance Executive Arthur Levine as Chief Financial Officer
29/05/2026
Mission-critical appointment with extensive public company, multinational, and emerging growth experience as SkyAI advances its agentic finance platform Marks the latest step in the Company’s evolution as it continues [...]
Imviva Biotech to Present Data from Clinical Studies of CTA313 and CTD402 Validating its ANSWER™ Allogeneic CAR-T Platform in Pediatric and Adult Patient Populations at EULAR and EHA 2026 Congresses
29/05/2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that it will present data on CTA313, its [...]
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
29/05/2026
Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA [...]
Sparrow Pharmaceuticals to Present Phase 2a Results for Clofutriben in Type 2 Diabetes at the 2026 American Diabetes Association (ADA) Scientific Session
29/05/2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals , a targeted cardiometabolic therapeutics company, today announced the presentation of results describing Phase 2a efficacy and safety data in patients [...]
New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma
29/05/2026
MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of Johnson & Johnson’s TECVAYLI ® as early as second line 1 TECVAYLI ® delivered deep and durable responses, with nearly two-thirds of [...]

Pages